Acute Myeloid Leukemia Clinical Trial

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

Summary

Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). Successful treatment of AML is dependent on what subtype of AML the participant has, and the age of the participant when diagnosed.

Venetoclax is an experimental drug that kills cancer cells by blocking a protein (part of a cell) that allows cancer cells to stay alive. This study is designed to see if adding venetoclax to azacitidine works better than azacitidine on its own.

This is a Phase 3, randomized, double-blind (treatment is unknown to participants and doctors), placebo controlled study in patients with AML who are >= 18 or more years old and have not been treated before. Participants who take part in this study should not be suitable for standard induction therapy (usual starting treatment). AbbVie is funding this study which will take place at approximately 180 hospitals globally and enroll approximately 400 participants.

In this study, 2/3 of participants will receive venetoclax every day with azacitidine and the remaining 1/3 will receive placebo (dummy) tablets with azacitidine.

Participants will continue to have study visits and receive treatment for as long as they are having a clinical benefit. The effect of the treatment on AML will be checked by taking blood, bone marrow, scans, measuring side effects and by completing health questionnaires. Blood and bone marrow tests will be completed to see why some people respond better than others. Additional blood tests will be completed for genetic factors and to see how long the drug remains in the body.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participant must have confirmation of Acute Myeloid Leukemia (AML) by World Health Organization (WHO) criteria, previously untreated and be ineligible for treatment with a standard cytarabine and anthracycline induction regimen due age or comorbidities.
Participant must be >= 18 years of age.
Participant must have a projected life expectancy of at least 12 weeks.

Participant must be considered ineligible for induction therapy defined by the following:

a. >= 75 years of age; or b. >= 18 to 74 years of age with at least one of the following comorbidities: i. Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 or 3; ii. Cardiac history of Congestive Heart Failure (CHF) requiring treatment or Ejection Fraction <= 50% or chronic stable angina; iii. Diffusing capacity of the Lung for Carbon Monoxide (DLCO) <= 65% or Forced Expiratory Volume in 1 second (FEV1) <= 65%; iv. Creatinine clearance >= 30 mL/min to < 45 ml/min; v. Moderate hepatic impairment with total bilirubin > 1.5 to <= 3.0 × Upper Limit of Normal (ULN); vi. Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy must be reviewed and approved by the AbbVie Therapeutic Medical Director during screening and before study enrollment.

Participant must have an ECOG Performance status:

0 to 2 for Participants >= 75 years of age or
0 to 3 for Participants >= 18 to 74 years of age.
Participant must have adequate renal function as demonstrated by a creatinine >= 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection.

Participant must have adequate liver function as demonstrated by:

aspartate aminotransferase (AST) <= 3.0 x ULN*
alanine aminotransferase (ALT) <= 3.0 x ULN*
bilirubin <= 1.5 x ULN* * Unless considered to be due to leukemic organ involvement

i. Subjects who are < 75 years of age may have a bilirubin of <= 3.0 x ULN

Female participants must be either postmenopausal defined as:

Age > 55 years with no menses for 12 or more months without an alternative medical cause.
Age ≤ 55 years with no menses for 12 or more months without an alternative medical cause AND an FSH level > 40 IU/L; or
Permanently surgical sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy); or
Women of Childbearing Potential (WOCBP) practicing at least one protocol specified method of birth control, starting at Study Day 1 through at least 90 days after the last dose of study drug.
Male Participants who are sexually active, must agree, from Study Day 1 through at least 90 days after the last dose of study drug, to practice the protocol specified contraception. Male subjects must agree to refrain from sperm donation from initial study drug administration through at least 90 days after the last dose of study drug.

Female participants of childbearing potential must have negative results for pregnancy test performed:

At Screening with a serum sample obtained within 14 days prior to the first study drug administration, and
Prior to dosing with urine sample obtained on Cycle 1 Day 1, if it has been > 7 days since obtaining the serum pregnancy test results.
Participant must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.

Exclusion Criteria:

Participant has received treatment with the following:

A hypomethylating agent, venetoclax and/or chemo therapeutic agent for Myelodysplastic syndrome (MDS).
Chimeric Antigen Receptor (CAR)-T cell therapy.
Experimental therapies for MDS or Acute Myeloid Leukemia (AML).
Current participation in another research or observational study.
Participant has history of myeloproliferative neoplasm (MPN) including myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia (CML) with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation.

Participant has the following:

a. Favorable risk cytogenetics such as t(8;21), inv(16) or t(16;16) or t(15;17) as per the National Comprehensive Cancer Network (NCCN) Guidelines Version 2, 2016 for Acute Myeloid Leukemia.

Participant has acute promyelocytic leukemia
Participant has known active central nervous system (CNS) involvement with AML.
Participant has known HIV infection (due to potential drug-drug interactions between antiretroviral medications and venetoclax) HIV testing will be performed at Screening, only if required per local guidelines or institutional standards.
Participant is known to be positive for hepatitis B or C infection [HCV Ab indicative of a previous or current infection; and/or positive HBs Ag or detected sensitivity on HBV DNA PCR test for HBc Ab and/or HBs Ab positivity] with the exception of those with an undetectable viral load within 3 months screening. Hepatitis B or C testing is not required.
Participant has received strong and/or moderate CYP3A inducers within 7 days prior to the initiation of study treatment; additional details as described in the protocol.
Participant has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Starfruit within 3 days prior to the initiation of study treatment.
Participant has a cardiovascular disability status of New York Heart Association Class > 2. Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal pain.
Participant has chronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, any other medical condition or known hypersensitivity to any of the study medications including excipients of azacitidine that in the opinion of the investigator would adversely affect his/her participating in this study.
Participant has a malabsorption syndrome or other condition that precludes enteral route of administration.
Participant exhibits evidence of other clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial or fungal).

Participant has a history of other malignancies within 2 years prior to study entry, with the exception of:

Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast;
Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent; requires discussion with TA MD.
Participant has a white blood cell count > 25 × 10^9/L. (Hydroxyurea or leukapheresis are permitted to meet this criterion.)

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 3

Estimated Enrollment:

400

Study ID:

NCT02993523

Recruitment Status:

Active, not recruiting

Sponsor:

AbbVie

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 164 Locations for this study

See Locations Near You

City of Hope /ID# 154105
Duarte California, 91010, United States
University of California, Los Angeles /ID# 154107
Los Angeles California, 90095, United States
University of California, Davis Comprehensive Cancer Center /ID# 162725
Sacramento California, 95817, United States
Emory Midtown Infectious Disease Clinic /ID# 162534
Atlanta Georgia, 30322, United States
Northwestern University Feinberg School of Medicine /ID# 201133
Chicago Illinois, 60611, United States
University of Chicago Medicine /ID# 154108
Chicago Illinois, 60637, United States
Fort Wayne Medical Oncology /ID# 157190
Fort Wayne Indiana, 46804, United States
Cotton-O'Neil Clinical Res Ctr /ID# 155136
Topeka Kansas, 66606, United States
Norton Cancer Institute /ID# 154992
Louisville Kentucky, 40202, United States
EMMC Cancer Care /ID# 154991
Brewer Maine, 04412, United States
Johns Hopkins University /ID# 154104
Baltimore Maryland, 21287, United States
Massachusetts General Hospital /ID# 200752
Boston Massachusetts, 02114, United States
Beth Israel Deaconess Medical Center /ID# 201155
Boston Massachusetts, 02215, United States
Dana-Farber Cancer Institute /ID# 167009
Boston Massachusetts, 02215, United States
Sepctrum Health Medical Center /ID# 159522
Grand Rapids Michigan, 49503, United States
Columbia Univ Medical Center /ID# 154101
New York New York, 10032, United States
Memorial Sloan Kettering Cancer Center-Koch Center /ID# 165077
New York New York, 10065, United States
Duke Cancer Center /ID# 154106
Durham North Carolina, 27710, United States
University of Pittsburgh MC /ID# 154102
Pittsburgh Pennsylvania, 15260, United States
Tennessee Oncology-Nashville Centennial /ID# 200854
Nashville Tennessee, 37203, United States
University of Texas MD Anderson Cancer Center /ID# 154100
Houston Texas, 77030, United States
Baylor Scott & White Medical Center- Temple /ID# 157191
Temple Texas, 76508, United States
University of Utah /ID# 157192
Salt Lake City Utah, 84112, United States
University Of Vermont Medical /ID# 157196
Burlington Vermont, 05405, United States
Princess Alexandra Hospital /ID# 154272
Woolloongabba Queensland, 4102, Australia
Royal Adelaide Hospital /ID# 154271
Adelaide South Australia, 5000, Australia
St Vincent's Hospital Melbourne /ID# 155094
Fitzroy Melbourne Victoria, 3065, Australia
Alfred Health /ID# 154275
Melbourne Victoria, 3004, Australia
The Royal Melbourne Hospital /ID# 155095
Parkville Victoria, 3050, Australia
Sir Charles Gairdner Hospital /ID# 163924
Nedlands Western Australia, 6009, Australia
Royal Perth Hospital /ID# 154274
Perth Western Australia, 6000, Australia
Universitaetsklinikum St. Poelten /ID# 167436
Sankt Poelten Niederoesterreich, 3100, Austria
Ordensklinikum Linz GmbH Barmherzige Schwestern /ID# 154888
Linz Oberoesterreich, 4010, Austria
Ordensklinikum Linz GmbH Elisabethinen /ID# 154885
Linz Oberoesterreich, 4010, Austria
Medizinische Universitaet Graz /ID# 157882
Graz Steiermark, 8036, Austria
Duplicate_Landeskrankenhaus Salzburg /ID# 169719
Salzburg , 5020, Austria
Hanusch Krankenhaus /ID# 155676
Wien , 1140, Austria
UZ Brussel /ID# 153393
Jette Bruxelles-Capitale, 1090, Belgium
UCL Saint-Luc /ID# 153391
Woluwe-Saint-Lambert Bruxelles-Capitale, 1200, Belgium
UZ Gent /ID# 153392
Gent Oost-Vlaanderen, 9000, Belgium
AZ Sint-Jan Brugge /ID# 154041
Brugge , 8000, Belgium
Hospital de Clinicas de Porto Alegre /ID# 157779
Porto Alegre Rio Grande Do Sul, 90035, Brazil
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto - USP /ID# 153099
Ribeirão Preto Sao Paulo, 14051, Brazil
Instituto de Ensino e Pesquisa São Lucas /ID# 157778
São Paulo Sao Paulo, 01236, Brazil
Instituto do Câncer do Estado de São Paulo - ICESP /ID# 153095
São Paulo Sao Paulo, 01246, Brazil
Tom Baker Cancer Centre /ID# 159645
Calgary Alberta, T2N 4, Canada
St. Paul's Hospital /ID# 159644
Vancouver British Columbia, V6Z 1, Canada
Juravinski Cancer Centre /ID# 153650
Hamilton Ontario, L8V 1, Canada
Ottawa Hospital Research Institute /ID# 153541
Ottawa Ontario, K1H 8, Canada
Princess Margaret Cancer Centre /ID# 153651
Toronto Ontario, M5G 2, Canada
Fujian Medical University Union Hospital /ID# 167314
Fuzhou Fujian, 35000, China
Nanfang Hospital of Southern Medical University /ID# 170148
Guangzhou Guangdong, 51051, China
The Second Hospital of Hebei Medical University /ID# 167316
Shijiazhuang Hebei, 05000, China
Henan Cancer Hospital /ID# 167320
Zhengzhou Henan, 45000, China
Tongji Hospital Tongji Medical College Huazhong University of Science and Techno /ID# 167315
Wuhan Hubei, 43002, China
Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 167493
Wuhan Hubei, 43002, China
Jiangsu Province Hospital /ID# 167489
Nanjing Jiangsu, 21002, China
The First Hospital of Jilin University /ID# 167490
Changchun Jilin, 13002, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 167318
Shanghai Shanghai, 20006, China
West China Hospital, Sichuan University /ID# 167492
Chengdu Sichuan, 61004, China
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 167487
Tianjin Tianjin, 30002, China
The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 167317
Hangzhou Zhejiang, 31000, China
Qilu Hospital of Shandong University /ID# 167485
Jinan , 25001, China
Clinical Hospital Dubrava /ID# 153515
Zagreb Grad Zagreb, 10000, Croatia
Klinicki bolnicki centar Zagreb /ID# 153383
Zagreb Grad Zagreb, 10000, Croatia
Duplicate_Klinicki bolnicki centar Osijek /ID# 153623
Osijek Osjecko-baranjska Zupanija, 31000, Croatia
Fakultni Nemocnice Brno /ID# 154019
Brno , 625 0, Czechia
Fakultni nemocnice Hradec Kralove /ID# 154021
Hradec Kralove , 500 0, Czechia
Fakultni nemocnice Ostrava /ID# 154017
Ostrava , 708 5, Czechia
Fakultni nemocnice Plzen /ID# 154018
Plzen , 305 9, Czechia
Aalborg University Hospital /ID# 154047
Aalborg Nordjylland, 9000, Denmark
Tampere University Hospital /ID# 154963
Tampere Pirkanmaa, 33520, Finland
Helsinki University Hospital /ID# 155223
Helsinki Uusimaa, 00290, Finland
Turku University Hospital /ID# 154964
Turku , 20520, Finland
CHU Bordeaux - Hopital Haut Leveque /ID# 153789
Pessac Gironde, 33604, France
Chu Angers /Id# 153792
Angers , 49933, France
AP-HP - Hopital Saint-Louis /ID# 153787
Paris , 75010, France
IUCT Oncopole /ID# 153788
Toulouse Cedex 9 , 31059, France
Universitaetsklinikum Ulm /ID# 153054
Ulm Baden-Wuerttemberg, 89081, Germany
Universitaetsklinikum Frankfurt /ID# 153060
Frankfurt am Main Hessen, 60590, Germany
Universitaetsklinikum Muenster /ID# 153059
Muenster Nordrhein-Westfalen, 48149, Germany
Universitaetsklinikum Halle (Saale) /ID# 153058
Halle (Saale) , 06120, Germany
Universitaetsklinikum Hamburg-Eppendorf (UKE) /ID# 153056
Hamburg , 20246, Germany
Medizinische Hochschule Hannover /ID# 153055
Hannover , 30625, Germany
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont /ID# 153812
Szeged Csongrad, 6725, Hungary
Debreceni Egyetem Klinikai Kozpont /ID# 153814
Debrecen Hajdu-Bihar, 4032, Hungary
Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz Josa Andras Okta /ID# 169854
Nyíregyháza Nyiregyhaza, 4400, Hungary
Somogy Megyei Kaposi Mor Oktato Korhaz /ID# 153813
Kaposvár Somogy, 7400, Hungary
Duplicate_Semmelweis Egyetem /ID# 153815
Budapest VIII , 1088, Hungary
Semmelweis Egyetem /ID# 153816
Budapest , 1085, Hungary
Del-pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet /ID# 158990
Budapest , 1097, Hungary
The Chaim Sheba Medical Center /ID# 154173
Ramat Gan Tel-Aviv, 52656, Israel
Tel Aviv Sourasky Medical Center /ID# 154175
Tel Aviv-Yafo Tel-Aviv, 64239, Israel
Assaf Harofeh Medical Center /ID# 158063
Be'Er Ya'Akov , 70300, Israel
Rambam Health Care Campus /ID# 154174
Haifa , 31096, Israel
Hadassah /ID# 154172
Jerusalem , 91120, Israel
Rabin Medical Center /ID# 154176
Petakh Tikva , 49414, Israel
Presidio Ospedaliero Vito Fazzi /ID# 170837
Lecce Puglia, 73100, Italy
Fondazione PTV Policlinico Tor Vergata /ID# 152881
Rome Roma, 00133, Italy
Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 171220
Ancona , 60126, Italy
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni /ID# 152875
Bergamo , 24127, Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna /ID# 152883
Bologna , 40138, Italy
Ospedale Policlinico San Martino /ID# 158104
Genova , 16132, Italy
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 152882
Milan , 20122, Italy
Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli /ID# 152879
Napoli , 80131, Italy
Grande Ospedale Metropolitano Bianchi Melacrino Morelli /ID# 152877
Reggio Calabria , 89124, Italy
Azienda Ospedaliero-Universitaria Sant'Andrea /ID# 152876
Rome , 00189, Italy
Aichi Cancer Center Hospital /ID# 200824
Nagoya-shi Aichi, 464-8, Japan
University of Fukui Hospital /ID# 167432
Yoshida-gun Fukui, 910-1, Japan
National Hospital Organization Kyushu Cancer Center /ID# 201111
Fukuoka-shi Fukuoka, 811-1, Japan
Kyushu University Hospital /ID# 169095
Fukuoka-shi Fukuoka, 812-8, Japan
Gunmaken Saiseikai Maebashi Hospital /ID# 168316
Maebashi-shi Gunma, 371-0, Japan
National Hospital Organization Mito Medical Center /ID# 168219
Higashi Ibaraki-gun Ibaraki, 311-3, Japan
Hitachi General Hospital /ID# 201109
Hitachi-shi Ibaraki, 317-0, Japan
Duplicate_Kyoto Prefectural University of Medicine /ID# 167661
Kyoto-shi Kyoto, 602-8, Japan
Tohoku University Hospital /ID# 169259
Sendai-shi Miyagi, 98085, Japan
Nagasaki University Hospital /ID# 168632
Nagasaki-shi Nagasaki, 852-8, Japan
Okayama University Hospital /ID# 204124
Okayama-shi Okayama, 700-8, Japan
Duplicate_Kindai University Hospital /ID# 167662
Osaka-sayama-shi Osaka, 589-8, Japan
Osaka Metropolitan University Hospital /ID# 169055
Osaka-shi Osaka, 545-8, Japan
Saitama Medical University International Medical Center /ID# 167814
Hidaka-shi Saitama, 350-1, Japan
Juntendo University Hospital /ID# 168309
Bunkyo-ku Tokyo, 113-8, Japan
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital /ID# 168639
Bunkyo-ku Tokyo, 113-8, Japan
The Jikei University Daisan Hospital /ID# 168745
Komae-shi Tokyo, 201-8, Japan
NTT Medical Center Tokyo /ID# 167975
Shinagawa-ku Tokyo, 141-8, Japan
Yamagata University Hospital /ID# 167634
Yamagata-shi Yamagata, 990-9, Japan
Duplicate_Konkuk University Medical Ctr /ID# 153973
Seoul Seoul Teugbyeolsi, 05030, Korea, Republic of
Seoul National University Hospital /ID# 153675
Seoul , 03080, Korea, Republic of
Samsung Medical Center /ID# 153674
Seoul , 06351, Korea, Republic of
Akershus universitetssykehus /ID# 154279
Nordbyhagen Akershus, 1474, Norway
Drammen Sykehus /ID# 154280
Drammen Buskerud, 3004, Norway
Haukeland University Hospital /ID# 154281
Bergen Hordaland, 5021, Norway
Sykehuset Ostfold Kalnes /ID# 157755
Gralum , 1714, Norway
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu /ID# 153389
Wroclaw Dolnoslaskie, 50-55, Poland
Osrodek Badan Klinicznych przy Szpitalu Specjalistycznym im. Ludwika Rydygiera w /ID# 169846
Krakow Malopolskie, 31-82, Poland
SP ZOZ Zespol Szpitali Miejskich w Chorzowie /ID# 153385
Chorzow Slaskie, 41-50, Poland
Duplicate_Hospital de Braga /ID# 154797
Braga , 4710-, Portugal
IPO Porto FG, EPE /ID# 154138
Porto , 4200-, Portugal
VA Caribbean Healthcare System /ID# 160507
San Juan , 00921, Puerto Rico
Kuzbass Regional Clinical Hospital /ID# 157461
Kemerovo Kemerovskaya Oblast, 65009, Russian Federation
Moscow State budget healthcare /ID# 155738
Moscow Moskva, 12528, Russian Federation
Nizhny Novgorod Regional Clinical Hospital named N.A. Semashko /ID# 153268
Nizhniy Novgorod Nizhegorodskaya Oblast, 60312, Russian Federation
Duplicate_Regional Oncology Dispensary /ID# 153264
Penza Penzenskaya Oblast, 44007, Russian Federation
State Institution of Health of the Ryazan Regional Clinical Hospital /ID# 157460
Ryazan Ryazanskaya Oblast, 39003, Russian Federation
Saratov State Medical University n.a. V.I. Razumovskiy /ID# 153267
Saratov Saratovskaya Oblast, 41001, Russian Federation
Federal State Budgetary Ins NRC for Hematology of MoH of Russian Federation /ID# 155740
Moscow , 12516, Russian Federation
Samara State Medical University /ID# 157462
Samara , 44309, Russian Federation
University of Pretoria /ID# 153682
Pretoria Gauteng, 0001, South Africa
Albert Alberts Stem Cell Transplant Centre /ID# 153684
Pretoria Gauteng, 0044, South Africa
Hospital Universitario de Navarra /ID# 153254
Pamplona Navarra, 31008, Spain
Hospital Clinic de Barcelona /ID# 153255
Barcelona , 08036, Spain
Hospital Santa Creu i Sant Pau /ID# 153193
Barcelona , 08041, Spain
Hospital Universitario de la Princesa /ID# 153256
Madrid , 28006, Spain
Hospital General Universitario Gregorio Maranon /ID# 153260
Madrid , 28007, Spain
Hospital Universitario 12 de Octubre /ID# 153258
Madrid , 28041, Spain
Hospital Universitario Virgen de la Victoria /ID# 153257
Malaga , 29010, Spain
Hospital Universitario y Politecnico La Fe /ID# 153259
Valencia , 46026, Spain
Akademiska Sjukhuset /ID# 153034
Uppsala Uppsala Lan, 751 8, Sweden
Uddevalla sjukhus /ID# 156875
Uddevalla Vastra Gotalands Lan, 451 8, Sweden
Dup_VO Hematologi /ID# 153174
Lund , 221 8, Sweden
Karolinska University Hospital /ID# 170003
Stockholm , 171 7, Sweden
Changhua Christian Hospital /ID# 153899
Changhua City, Changhua County , 50006, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 153902
Kaohsiung , 807, Taiwan
China Medical University Hospital /ID# 153904
Taichung City , 40447, Taiwan
National Taiwan University Hospital /ID# 153900
Taipei City , 100, Taiwan
Hacettepe University Faculty of Medicine /ID# 202073
Ankara , 06100, Turkey
Ankara Universitesi Fakultesi /ID# 155200
Ankara , 06620, Turkey
Ondokuz Mayis Universitesi Tip /ID# 155201
Samsun , 55139, Turkey
Kyiv city clinical hospital #9 /ID# 153510
Kiev Vinnytska Oblast, 04112, Ukraine
Municipal Non-Profit Enterprise City Clinical Hospital No.4 of Dnipro City Counc /ID# 153511
Dnipro , 49102, Ukraine
Kyiv Regional Onco Dispensary /ID# 153514
Kyiv , 04107, Ukraine
Poltava Reg Clin Hosp Sklifoso /ID# 153513
Poltava , 36011, Ukraine

How clear is this clinincal trial information?

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 3

Estimated Enrollment:

400

Study ID:

NCT02993523

Recruitment Status:

Active, not recruiting

Sponsor:


AbbVie

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.